Limoxifen

Limoxifen B.V. is a Dutch biotechnology company focused on developing treatments for adverse drug reactions induced by selective estrogen-receptor modulators (SERMs) like Tamoxifen. Founded by Adriaan Tuiten, the company leverages expertise in neurobiology and endocrinology to address cognitive and sexual side effects in breast cancer survivors. Its lead program involves the use of guanfacine, a noradrenergic alpha-2A agonist, to mitigate memory loss and attention deficits associated with adjuvant hormonal therapy. Limoxifen also explores combinations of testosterone and aromatase inhibitors to manage hormone deficiency symptoms while minimizing estrogenic risks.